Related Experiment Video
Updated: Aug 10, 2026
08:17
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment
R Leigh1, M M M Pizzichini, M M Morris
1Firestone Institute for Respiratory Health, St. Joseph's Healthcare and McMaster University, Hamilton, ON, Canada.
The European Respiratory Journal
|February 1, 2006
Summary
Sputum eosinophilia predicts benefit from inhaled corticosteroids in COPD patients. Patients with high eosinophil counts showed improved symptoms and lung function with budesonide treatment.
Area of Science:
- Pulmonology
- Respiratory Medicine
- Clinical Pharmacology
Background:
- The efficacy of inhaled corticosteroids (ICS) in managing chronic obstructive pulmonary disease (COPD) is debated.
- Identifying biomarkers to predict ICS response is crucial for personalized COPD management.
Purpose of the Study:
- To determine if sputum eosinophilia predicts clinical benefit from inhaled corticosteroid therapy.
- To assess the impact of budesonide on patients with moderate-to-severe, stable, smoking-related COPD.
Main Methods:
- A 4-week, single-blind, placebo-controlled crossover study involving 40 COPD patients.
- Patients received inhaled placebo then budesonide (1,600 microg/day), with double-blind sputum analysis.
- Outcomes included spirometry, quality of life (CRQ), and 6-minute walk test.
Main Results:
- Sputum eosinophilia (≥3%) was found in 38% of patients.
- Budesonide normalized eosinophil counts and significantly improved dyspnea scores (0.8 vs 0.3) and FEV1 (100 mL vs 0 mL) compared to placebo in eosinophilic patients.
- No significant improvements were observed in non-eosinophilic patients.
Conclusions:
- Sputum eosinophilia is a predictor of short-term clinical benefit from high-dose ICS in COPD.
- This finding supports a personalized approach to ICS use in COPD based on eosinophil counts.
Related Concept Videos
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation